Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi Chemical Says It’s Exploring All Options for Portfolio Reform
After a Nikkei report on the potential divestment of its pharmaceutical business, Mitsubishi Chemical Group said on January 21 that it is considering “all options” in pursuing its portfolio review, including divestitures. On January 20, the Japanese business daily reported…
To read the full story
Related Article
- Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
July 2, 2025
- Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
- Bain Strikes Deal to Buy Mitsubishi Tanabe
February 7, 2025
BUSINESS
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…